Advertisement

Topics

Onxeo S.A. Company Profile

00:52 EDT 21st September 2018 | BioPortfolio

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.


News Articles [20 Associated News Articles listed on BioPortfolio]

Onxeo Provides Financial Update

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and r...

Onxeo S.A.: Combined General Meeting on May 16, 2018

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Onxeo S.A.: Publication of 2017 Registration Document

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Summary of Onxeo's Liquidity Contract with CM-CIC Securities

Regulatory News: Pursuant to the liquidity contract granted to CM-CIC SECURITIES regarding Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) shares, the following resources were listed in the liquidity accou...

Onxeo: Publication of the 2018 Half-Yearly Financial Report

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in part...

Onxeo to Attend Key Investor and Partnering Conferences in the Coming Months

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today a...

Onxeo to Present at BIO International Convention in Boston

PARIS–(BUSINESS WIRE)–Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in on...

Onxeo (ONXEO) - Phase I with AsiDNA iv starts; first data in H218

Edison Investment Research - Pharmaceutical & healthcare - Onxeo: On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via sys...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Onxeo S.A.

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

Onxeo SA

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

More Information about "Onxeo S.A." on BioPortfolio

We have published hundreds of Onxeo S.A. news stories on BioPortfolio along with dozens of Onxeo S.A. Clinical Trials and PubMed Articles about Onxeo S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Onxeo S.A. Companies in our database. You can also find out about relevant Onxeo S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record